CareDx vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CareDx Inc (CDNA)

Q3 20262 Jul – 31 Jul 2026

▲3

CareDx surges on Medicare win, Naveris deal, and raised guidance

Medicare finalizes coverage for transplant tests Medicare locked in coverage for CareDx's AlloSure, AlloMap, and AlloSeq transplant rejection tests, effective August 30, 2026. This removes a big payment uncertainty, making it easier for doctors to order the tests and for CareDx to get paid, which sent the stock up over 35%.
This is the single biggest new regulatory catalyst that directly boosts revenue visibility and drove the period's sharpest price move.
Acquires Naveris for $260 million, enters oncology CareDx bought Naveris for $160 million upfront plus up to $100 million in milestone payments, adding NavDx—a Medicare-covered blood test for HPV-related cancers. This opens a new $12 billion market and is expected to add revenue immediately, giving the company a second growth engine beyond transplant care.
This is a major strategic expansion that diversifies revenue and was a key new event in the period.
Q2 revenue jumps 52%, full-year guidance raised CareDx reported second-quarter revenue of $132 million, up 52% from a year ago, and more than tripled adjusted net income to $20 million. Management raised full-year revenue guidance to $490–500 million and EBITDA to $66–78 million, signaling strong demand for its transplant monitoring tests.
This is the latest hard financial proof that the business is accelerating, directly supporting a higher stock price.

July 20262 Jul – 31 Jul 2026

▲3

CareDx surges on Medicare win, Naveris deal, and raised guidance

Medicare finalizes coverage for transplant tests Medicare locked in coverage for CareDx's AlloSure, AlloMap, and AlloSeq transplant rejection tests, effective August 30, 2026. This removes a big payment uncertainty, making it easier for doctors to order the tests and for CareDx to get paid, which sent the stock up over 35%.
This is the single biggest new regulatory catalyst that directly boosts revenue visibility and drove the period's sharpest price move.
Acquires Naveris for $260 million, enters oncology CareDx bought Naveris for $160 million upfront plus up to $100 million in milestone payments, adding NavDx—a Medicare-covered blood test for HPV-related cancers. This opens a new $12 billion market and is expected to add revenue immediately, giving the company a second growth engine beyond transplant care.
This is a major strategic expansion that diversifies revenue and was a key new event in the period.
Q2 revenue jumps 52%, full-year guidance raised CareDx reported second-quarter revenue of $132 million, up 52% from a year ago, and more than tripled adjusted net income to $20 million. Management raised full-year revenue guidance to $490–500 million and EBITDA to $66–78 million, signaling strong demand for its transplant monitoring tests.
This is the latest hard financial proof that the business is accelerating, directly supporting a higher stock price.

Latest2 Jul – 31 Jul 2026

▲3

CareDx surges on Medicare win, Naveris deal, and raised guidance

Medicare finalizes coverage for transplant tests Medicare locked in coverage for CareDx's AlloSure, AlloMap, and AlloSeq transplant rejection tests, effective August 30, 2026. This removes a big payment uncertainty, making it easier for doctors to order the tests and for CareDx to get paid, which sent the stock up over 35%.
This is the single biggest new regulatory catalyst that directly boosts revenue visibility and drove the period's sharpest price move.
Acquires Naveris for $260 million, enters oncology CareDx bought Naveris for $160 million upfront plus up to $100 million in milestone payments, adding NavDx—a Medicare-covered blood test for HPV-related cancers. This opens a new $12 billion market and is expected to add revenue immediately, giving the company a second growth engine beyond transplant care.
This is a major strategic expansion that diversifies revenue and was a key new event in the period.
Q2 revenue jumps 52%, full-year guidance raised CareDx reported second-quarter revenue of $132 million, up 52% from a year ago, and more than tripled adjusted net income to $20 million. Management raised full-year revenue guidance to $490–500 million and EBITDA to $66–78 million, signaling strong demand for its transplant monitoring tests.
This is the latest hard financial proof that the business is accelerating, directly supporting a higher stock price.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.